Moderna (NASDAQ: MRNA) is on a roll. Entering the fourth quarter of 2022, the biotech's shares were down more than 40% from their previous high. Over the last three months, though, they've skyrocketed.

The news still isn't good for the company on the COVID-19 front. Moderna expects to report sales of $18.4 billion for its COVID-19 vaccine in 2022. But Spikevax sales will decline sharply this year. The reality is that COVID-19 will almost certainly wane in importance for Moderna. But there could be a new big growth story for the vaccine stock.

Respiratory syncytial virus (RSV) presents a huge healthcare problem. It's highly contagious and especially concerning for infants and senior adults. Analysts at SVB Leerink estimate that the RSV vaccine market could top $10 billion by 2030, with the senior adult opportunity making up at least $7 billion of the total.

Continue reading

Source Fool.com